31/01/2015 12:44:17 Free Membership Login

Mylan News (NASDAQ:MYL)

DateTimeSource
Headline
01/29/201511:18AMPRNUSMylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty...
Mylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business PR Newswire PITTSBURGH, Jan. 29, 2015 PITTSBURGH, Jan. 29, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced that at a Special Meeting of Shareholders held Jan... More...>>
01/29/20159:04AMDJNAbbott Laboratories Profit Grows 54%
By Tess Stynes Abbott Laboratories said its fourth-quarter earnings soared as the company posted stronger revenue in its nutrition and diagnostics businesses, although currency fluctuations weighed on sales growth. Abbott has been realigning its business in a series of deals. Last year Abbott reached an agreement to shed... More...>>
01/26/201510:58AMPRNUSMylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent
Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent PR Newswire PITTSBURGH and HYDERABAD, India, Jan. 26, 2015 PITTSBURGH and HYDERABAD, India, Jan. 26, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited is expanding... More...>>
01/20/20155:13PMDJNSupreme Court Sides With Teva in Patent Case on Copaxone -- 2nd Update
By Brent Kendall And Ashby Jones The U.S. Supreme Court on Tuesday reversed an appeals court ruling that invalidated a Teva Pharmaceutical Industries Ltd. patent on the blockbuster multiple-sclerosis drug Copaxone, giving the drug maker a new opportunity to forestall generic competition. The ruling breathes new life into... More...>>
01/20/20153:29PMDJNSupreme Court Sides With Teva in Patent Case on Copaxone -- 2nd Update
By Brent Kendall And Ashby Jones The U.S. Supreme Court on Tuesday reversed an appeals court ruling that invalidated a Teva Pharmaceutical Industries Ltd. patent on the blockbuster multiple-sclerosis drug Copaxone, giving the drug maker a new opportunity to forestall generic competition. The ruling breathes new life into... More...>>
01/20/201512:59PMDJNSupreme Court Sides With Teva in Patent Case on Copaxone -- Update
By Brent Kendall And Ashby Jones The U.S. Supreme Court on Tuesday reversed an appeals court ruling that invalidated a Teva Pharmaceutical Industries Ltd. patent on the blockbuster multiple-sclerosis drug Copaxone, giving the drug maker a new opportunity to forestall generic competition. The ruling breathes new life into... More...>>
01/20/201512:51PMPRNUSU.S. Supreme Court Partially Modifies Standard of Review of Patent Claim Construction and Remands Review of Teva's '808 Paten...
U.S. Supreme Court Partially Modifies Standard of Review of Patent Claim Construction and Remands Review of Teva's '808 Patent on Copaxone® to Federal Circuit Court of Appeals PR Newswire PITTSBURGH, Jan. 20, 2015 PITTSBURGH, Jan. 20, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Supreme... More...>>
01/20/201511:02AMDJNSupreme Court Sides With Teva in Patent Case on Copaxone
By Brent Kendall WASHINGTON-The U.S. Supreme Court on Tuesday reversed an appeals court ruling that invalidated a Teva Pharmaceutical Industries Ltd. patent on the blockbuster multiple-sclerosis drug Copaxone, giving the drug maker a new opportunity to forestall generic competition. The court, in a 7-2 opinion by Justice... More...>>
01/15/20152:29PMPRNUSMylan Launches Generic Epivir-HBV® Tablets
Mylan Launches Generic Epivir-HBV® Tablets PR Newswire PITTSBURGH, Jan. 15, 2015 PITTSBURGH, Jan. 15, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's Epivir-HBV®. Mylan received final approval from the... More...>>
01/05/20151:00PMPRNUSMylan Launches Generic Diovan® Tablets
Mylan Launches Generic Diovan® Tablets PR Newswire PITTSBURGH, Jan. 5, 2015 PITTSBURGH, Jan. 5, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of Novartis' Diovan® Tablets. Mylan received final... More...>>
12/31/20146:00AMPRNUSSouth African National Department of Health Selects Mylan as a Leading Supplier for 2015/2018 Antiretroviral Tender
South African National Department of Health Selects Mylan as a Leading Supplier for 2015/2018 Antiretroviral Tender PR Newswire JOHANNESBURG and PITTSBURGH, Dec. 31, 2014 JOHANNESBURG and PITTSBURGH, Dec. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary in India, Mylan Laboratories... More...>>
12/22/20147:30AMPRNUSMylan Launches First Generic Version of Vivelle-DOT®
Mylan Launches First Generic Version of Vivelle-DOT® PR Newswire PITTSBURGH, Dec. 22, 2014 PITTSBURGH, Dec. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly... More...>>
12/17/20149:00AMPRNUSMylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference PR Newswire PITTSBURGH, Dec. 17, 2014 PITTSBURGH, Dec. 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33rd... More...>>
12/11/20147:30AMPRNUSMylan Launches Generic Robaxin® Injection
Mylan Launches Generic Robaxin® Injection PR Newswire PITTSBURGH, Dec. 11, 2014 PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple... More...>>
12/11/20147:00AMPRNUSMylan Launches First Generic Version of Orapred ODT®
Mylan Launches First Generic Version of Orapred ODT® - Company awarded 180 days of marketing exclusivity - PR Newswire PITTSBURGH, Dec. 11, 2014 PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg... More...>>
12/10/20147:30AMPRNUSMylan Launches One of First Available Generic Versions of Celebrex® Capsules
Mylan Launches One of First Available Generic Versions of Celebrex® Capsules PR Newswire PITTSBURGH, Dec. 10, 2014 PITTSBURGH, Dec. 10, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions... More...>>
12/08/20145:01AMPRNUSWorld TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017
World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017 PR Newswire PITTSBURGH and NEW YORK, Dec. 8, 2014 PITTSBURGH and NEW YORK, Dec. 8, 2014 /PRNewswire/ -- World TeamTennis (WTT), the innovative leader in professional team tennis competition, and Mylan (Nasdaq: MYL), one of the world's leading... More...>>
12/04/201411:39AMPRNUSMylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration wit...
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire LONDON and PITTSBURGH, Dec. 4, 2014 LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced... More...>>
12/04/201411:29AMPRNCAMylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration wit...
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative Canada NewsWire LONDON and PITTSBURGH, Dec. 4, 2014 LONDON and PITTSBURGH, Dec. 4, 2014 /CNW/ -- Mylan Inc. (Nasdaq: MYL) today announced that... More...>>
12/04/201411:29AMPRNUSMylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration wit...
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire LONDON and PITTSBURGH, Dec. 4, 2014 LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq myl150131 12:44